Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 2:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 1,866 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
Interventions: Pembrolizumab, Olaparib, Radiation; Drug · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Healthy Volunteer
Interventions: AI-1000 G2, PFS-NSD, Tocilizumab; Device · Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 189 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 3
States / cities: Lenexa, Kansas • Marlton, New Jersey • Salt Lake City, Utah

Conditions: Pharmacokinetics, Safety, Food-drug Interaction
Interventions: 200 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL, 700 mg resveratrol as JOTROL, 500 mg resveratrol as JOTROL administered to assess influence of food; Drug
Lead sponsor: Jupiter Orphan Therapeutics Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Solid Tumors
Interventions: Sterile Compound C31510 for Injection; Drug
Lead sponsor: BPGbio; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Santa Monica, California

Conditions: Feasibility, Diet, Healthy
Interventions: Super Chef: Family Fun in the Kitchen!; Behavioral
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 10 Years to 65 Years
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epilepsy, Seizures
Interventions: Transcranial Direct Current Stimulation; Device
Lead sponsor: Spaulding Rehabilitation Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 2 Diabetes Mellitus
Interventions: Sotagliflozin (SAR439954), Placebo, Metformin, Sulfonylurea; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 507 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 28
States / cities: Litchfield Park, Arizona • Peoria, Arizona • Greenbrae, California + 25 more

Conditions: Blepharitis
Interventions: Azithromycin ophthalmic solution, 1%, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 314 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 26
States / cities: Scottsdale, Arizona • Fayetteville, Arkansas • Artesia, California + 21 more

Conditions: Opioid-use Disorder
Interventions: Treatment Navigation (Intervention), Control; Behavioral · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 70 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 5
States / cities: Auburn, Washington • Burien, Washington • Federal Way, Washington + 2 more

Conditions: Healthy Volunteers
Interventions: Vonoprazan ODT-1 or ODT-2 without Water, Vonoprazan ODT-1 or ODT-2 with Water, Vonoprazan (Reference); Drug
Lead sponsor: Phathom Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Behavior, Child
Interventions: TCIT, Booster; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 12 Months and older
Enrollment: 622 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 4
States / cities: Miami, Florida

Conditions: Healthy
Interventions: Levetiracetam, Keppra®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Infections, Human Immunodeficiency Virus and Herpesviridae
Interventions: GSK1349572, Fosamprenavir, Ritonavir; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Tinnitus, Subjective, Hyperacusis, Hearing Disorders
Interventions: Transcranial Direct Current Stimulation (tDCS), Sham TDCS; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 80 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Acute Myeloid Leukemia
Interventions: Arsenic trioxide, Low-dose cytarabine alone; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 60 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 11
States / cities: Los Angeles, California • Chicago, Illinois • Indianapolis, Indiana + 6 more

Conditions: Diabetic Peripheral Neuropathic Pain
Interventions: LY3526318, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 35
States / cities: Chandler, Arizona • Glendale, Arizona • Phoenix, Arizona + 28 more

Conditions: Interstitial Lung Disease
Interventions: Amitriptyline 25 MG, Amitriptyline 50 MG, Duloxetine 30 MG, Duloxetine 60 MG, Placebo 30 MG, Placebo 60 MG; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Opioid Use Disorder, Opioid-related Disorders
Interventions: SUBOXONE sublingual film, RBP-6000; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 775 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 42
States / cities: Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 37 more

Conditions: Obsessive-Compulsive Disorder
Interventions: Summit RC+S System with ECoG Paddles, One Month Blinded Discontinuation Period:; Device · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 5 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Pittsburgh, Pennsylvania • Providence, Rhode Island • Houston, Texas

Conditions: Parkinson's Disease, Gait Impairment
Interventions: Methylphenidate (MPD), Placebo; Drug
Lead sponsor: University of Cincinnati; Other
Eligibility: 35 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Naltrexone, Methylphenidate Abuse
Interventions: Placebo, Methylphenidate 60 mg, Treatment Phase Sequence 4213, Treatment Phase Sequence 2134, Treatment Phase Sequence 1342, Treatment Phase Sequence 3421; Drug
Lead sponsor: Avekshan LLC; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 94 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Congestive Heart Failure
Interventions: Nesiritide, Tadalafil, Placebo, Saline load; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years to 90 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Insomnia Disorder
Interventions: ACT-541468, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 65 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 5
States / cities: Brandon, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more

Conditions: Epilepsy
Interventions: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH); Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 4
States / cities: Portland, Maine • Worcester, Massachusetts • Lebanon, New Hampshire + 1 more

Search by objective public record fields.

A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer

A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers

JOTROL PK, Safety, and Food Effect Assessment

Safety Study of Sterile Compound C31510 for Injection to Subjects With Solid Tumors

Super Chef - an Online Program Promoting the Mediterranean Dietary Pattern to Lower Income Families

Closed-loop System Using Transcranial Direct Current Stimulation (tDCS) for Epilepsy

Efficacy and Safety of Sotagliflozin Versus Placebo in Participants With Type 2 Diabetes Mellitus on Background of Sulfonylurea Alone or With Metformin

The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)

Treatment Navigation for Opioid Use Disorder

A Study to Evaluate Two Vonoprazan Orally Disintegrating Tablet Formulations Administered Without Water or Mixed With Water and Administered Via a Syringe Relative to the Vonoprazan Tablet in Healthy Participants

Teacher Child Interaction Training (TCIT): Randomized Control Trial

Levetiracetam 1000 mg Under Non-Fasting Conditions

GSK1349572 Drug Interaction Study With Fosamprenavir/Ritonavir

Treatment of Tinnitus With Noninvasive Neuromodulation and Listening Therapy

Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia

Chronic Pain Master Protocol (CPMP): A Study of LY3526318 in Participants With Diabetic Peripheral Neuropathic Pain

Efficacy of Two Doses of Duloxetine & Amitriptyline in Interstitial Lung Disease-related Cough

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

Phase II Adaptive Deep Brain Stimulation for Obsessive-Compulsive Disorder

Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease

Study for Naltrexone on the Abuse Potential of Methylphenidate

Tadalafil and Nesiritide as Therapy in Pre-clinical Heart Failure

Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder

HOBSCOTCH Phase II